Table 3 Proportion of patients achieving ≥ 4-point reductions in SGRQ total score, by baseline characteristics

ITT population

 Patients with ≥ 4-point reduction in SGRQ total score, n (%)

335/466 (72)

256/465 (55)

 Odds ratio (mepolizumab/placebo), 95% CI; p-value

2.17 (1.63, 2.87); p < 0.001

Age at asthma onset: < 18 years

 Patients with ≥ 4-point reduction in SGRQ total score, n (%)

90/130 (69)

65/122 (53)

 Odds ratio (mepolizumab/placebo), 95% CI

1.95 (1.12, 3.38)

Age at asthma onset: 18–< 40 years

 Patients with ≥ 4-point reduction in SGRQ total score, n (%)

123/173 (71)

96/171 (56)

 Odds ratio (mepolizumab/placebo), 95% CI

2.17 (1.34, 3.51)

Age at asthma onset: ≥ 40 years

 Patients with ≥ 4-point reduction in SGRQ total score, n (%)

121/162 (75)

95/172 (55)

 Odds ratio (mepolizumab/placebo), 95% CI

2.80 (1.70, 4.62)

Lung function: ≤ 60% predicted FEV₁

 Patients with ≥ 4-point reduction in SGRQ total score, n (%)

171/243 (70)

132/242 (55)

 Odds ratio (mepolizumab/placebo), 95% CI

2.13 (1.44, 3.16)

Lung function: > 60–80% predicted FEV₁

 Patients with ≥ 4-point reduction in SGRQ total score, n (%)

137/177 (77)

98/176 (56)

 Odds ratio (mepolizumab/placebo), 95% CI

3.03 (1.84, 4.99)

Lung function: ≥ 80% predicted FEV₁

 Patients with ≥ 4-point reduction in SGRQ total score, n (%)

27/46 (59)

26/47 (55)

 Odds ratio (mepolizumab/placebo), 95% CI

2.12 (0.70, 6.48)